



Clinical trial results:

Recombinant Human Insulin-Like Growth Factor-1 (rhIGF-1) Treatment of Short Stature Associated With Primary IGF-1 Deficiency: A Multicenter, Open-Label, Concentration-Controlled Trial

Summary

EudraCT number	2019-001095-11
Trial protocol	Outside EU/EEA
Global end of trial date	14 January 2009

Results information

Result version number	v1 (current)
This version publication date	22 September 2019
First version publication date	22 September 2019

Trial information

Trial identification

Sponsor protocol code	MS308
-----------------------	-------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00125190
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Ipsen Pharma
Sponsor organisation address	65 Quai Georges Gorse, Boulogne Billancourt, France, 92100
Public contact	Medical Director, Ipsen Pharma, clinical.trials@ipsen.com
Scientific contact	Medical Director, Ipsen Pharma, clinical.trials@ipsen.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 January 2009
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	14 January 2009
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The objective of this study was to assess the effects of once daily (QD) dosing with rhIGF-1 in increasing height velocity in prepubertal subjects with growth failure associated with primary insulin-like growth factor deficiency (IGFD).

Protection of trial subjects:

The study was conducted in accordance with Good Clinical Practice, as set out in the Code of Federal Regulations (CFR) 21 CFR paragraphs 50 and 312.60. International Conference on Harmonisation E6, (1996), the ethical principles that have their origins in the Declaration of Helsinki (revised Edinburgh, 2000), and applicable national and local regulatory requirements. In this pediatric trial, the Investigator or his/her delegate obtained written informed consent signed by each subject's parent or a duly authorized representative prior to conducting any protocol-related activity.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	12 January 2005
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 45
Worldwide total number of subjects	45
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	36
Adolescents (12-17 years)	9
Adults (18-64 years)	0
From 65 to 84 years	0

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details:

First subject screened: 12 January 2005. Last subject completed: 14 January 2009. 12 investigators screened subjects, 1 did not enroll any subjects. 89 subjects were screened, 41 were ineligible, 3 declined treatment and 45 were treated and analyzed.

Pre-assignment

Screening details:

Screening consisted of two-staged clinic visits for up to 6 weeks, and included the following evaluations: medical history, complete physical examination, measurements of serum IGF-1 and IGF-1 binding proteins (IGFBP-1, IGFBP-2 and IGFBP-3), growth hormone (GH) binding protein, acid-labile subunit (ALS), GH stimulation test.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Arm title	rhIGF-1 QD
-----------	------------

Arm description:

During the treatment phase (Day 1 to Week 86), subjects received subcutaneous (SC) injections of rhIGF-1 at an initial dose of 60 microgram per kilogram (mcg/kg) QD starting on Day 1 (Visit 3). From Week 2 (Visit 4) subsequent dose adjustments were made in order to achieve the target serum IGF-1 concentration for the subject's age and sex.

Arm type	Experimental
Investigational medicinal product name	rhIGF-1
Investigational medicinal product code	
Other name	Increlex®, Mecasermin
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

An initial dose of 60 mcg/kg QD with subsequent dose adjustments made in order to achieve the target serum IGF-1 concentration for the subject's age and sex. The maximum dose in any circumstance was 240 mcg/kg/day. The injection sites were rotated to minimize potential injection site reactions.

Number of subjects in period 1	rhIGF-1 QD
Started	45
Completed 34 weeks of study	43
Completed	30
Not completed	15
Adverse event, non-fatal	1
Subject/Parent Decision	7
Non-compliance	2
Unspecified	1
Lost to follow-up	4

Baseline characteristics

Reporting groups

Reporting group title	rhIGF-1 QD
-----------------------	------------

Reporting group description:

During the treatment phase (Day 1 to Week 86), subjects received subcutaneous (SC) injections of rhIGF-1 at an initial dose of 60 microgram per kilogram (mcg/kg) QD starting on Day 1 (Visit 3). From Week 2 (Visit 4) subsequent dose adjustments were made in order to achieve the target serum IGF-1 concentration for the subject's age and sex.

Reporting group values	rhIGF-1 QD	Total	
Number of subjects	45	45	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	36	36	
Adolescents (12-17 years)	9	9	
Adults (18-64 years)	0	0	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	8.7		
standard deviation	± 2.8	-	
Gender categorical			
Units: Subjects			
Female	7	7	
Male	38	38	
Race/Ethnicity, Customized			
Units: Subjects			
Black	1	1	
Hispanic	12	12	
White	31	31	
Other	1	1	
Body Mass Index Standard Deviation (SD) Score			
Units: SDs			
arithmetic mean	-0.4		
standard deviation	± 0.7	-	
Bone Age Imputed			
Units: years			
arithmetic mean	7.2		
standard deviation	± 2.6	-	
Height for Age SD Score			
Units: SDs			
arithmetic mean	-2.7		

standard deviation	± 0.6	-	
IGFBP-3 SD Score			
Units: SDs			
arithmetic mean	-0.7		
standard deviation	± 1.0	-	
IGF-1 SD Score			
Units: SDs			
arithmetic mean	-2.6		
standard deviation	± 0.5	-	
Maximum Stimulated GH			
Units: nanogram per milliliter			
arithmetic mean	20.5		
standard deviation	± 9.9	-	
Weight for Age SD Score			
Units: SDs			
arithmetic mean	-2.3		
standard deviation	± 0.7	-	

End points

End points reporting groups

Reporting group title	rhIGF-1 QD
Reporting group description:	
During the treatment phase (Day 1 to Week 86), subjects received subcutaneous (SC) injections of rhIGF-1 at an initial dose of 60 microgram per kilogram (mcg/kg) QD starting on Day 1 (Visit 3). From Week 2 (Visit 4) subsequent dose adjustments were made in order to achieve the target serum IGF-1 concentration for the subject's age and sex.	

Primary: Height Velocity Over the Study Period Pretreatment (Week 0) - 34 Weeks: Intent to Treat (ITT) Population

End point title	Height Velocity Over the Study Period Pretreatment (Week 0) - 34 Weeks: Intent to Treat (ITT) Population ^[1]
-----------------	---

End point description:

Height was measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. The subject was repositioned between each measurement. The ITT principle was used for the primary analysis, with imputation of missing height velocity and missing height SD score. Height velocity during an interval of time is defined as the change in height during the time interval divided by the duration of the time interval.

End point type	Primary
----------------	---------

End point timeframe:

Pretreatment to Week 34

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistical analysis was performed for the outcome measure.

End point values	rhIGF-1 QD			
Subject group type	Reporting group			
Number of subjects analysed	45			
Units: centimeter per year (cm/yr)				
arithmetic mean (standard deviation)	7.0 (± 1.5)			

Statistical analyses

No statistical analyses for this end point

Primary: Height Velocity Over the Study Period 34 - 86 Weeks: ITT Population

End point title	Height Velocity Over the Study Period 34 - 86 Weeks: ITT Population ^[2]
-----------------	--

End point description:

Height was measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. The subject was repositioned between each measurement. The ITT principle was used for the primary analysis, with imputation of missing height velocity and missing height SD score. Height velocity during an interval of time is defined as the change in height during the time interval divided by the duration of the time interval. Only subjects in the ITT population who continued past Week 34 were included in the analysis.

End point type	Primary
----------------	---------

End point timeframe:

Weeks 34 to 86

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistical analysis was performed for the outcome measure.

End point values	rhIGF-1 QD			
Subject group type	Reporting group			
Number of subjects analysed	40			
Units: cm/yr				
arithmetic mean (standard deviation)	6.7 (± 1.8)			

Statistical analyses

No statistical analyses for this end point

Secondary: Changes in Height SD Score From Pretreatment to Week 34: ITT Population

End point title	Changes in Height SD Score From Pretreatment to Week 34: ITT Population
-----------------	---

End point description:

Height was measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. The subject was repositioned between each measurement. The SD score is calculated as the subject value minus the mean divided by the standard deviation. The mean and the standard deviation vary depending on the age and sex of the child. The ITT principle was used for missing height SD score.

End point type	Secondary
----------------	-----------

End point timeframe:

Pretreatment and Week 34

End point values	rhIGF-1 QD			
Subject group type	Reporting group			
Number of subjects analysed	45			
Units: SDs				
arithmetic mean (standard deviation)	0.21 (± 0.20)			

Statistical analyses

No statistical analyses for this end point

Secondary: Changes in Height SD Score From Pretreatment to Week 86: ITT Population

End point title	Changes in Height SD Score From Pretreatment to Week 86: ITT Population
-----------------	---

End point description:

Height was measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Subjects were repositioned between each measurement. The SD score is calculated as the patient value minus the mean divided by the standard deviation. The mean and the standard deviation vary depending on the age and sex of the child. The ITT principle was used for missing height SD score. Only subjects in the ITT population who continued past Week 86 were included in the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Pretreatment and Week 86

End point values	rhIGF-1 QD			
Subject group type	Reporting group			
Number of subjects analysed	40			
Units: SDs				
arithmetic mean (standard deviation)	0.45 ($\pm$ 0.39)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change in Bone Age From Pretreatment to Week 86 Minus Change in Chronological Age: ITT Population

End point title	Change in Bone Age From Pretreatment to Week 86 Minus Change in Chronological Age: ITT Population
-----------------	---

End point description:

Plain X-rays of the left hand and wrist were exposed for bone age appraisal. The films were sent to a central facility for standardized evaluation. Subjects who had both pretreatment and Week 86 measurements were included in the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Pretreatment to Week 86

End point values	rhIGF-1 QD			
Subject group type	Reporting group			
Number of subjects analysed	30			
Units: years				
arithmetic mean (standard deviation)	0.2 ($\pm$ 0.68)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Changes in Serum Concentration of IGFBP-1 From Pretreatment to Week 86

End point title	Percent Changes in Serum Concentration of IGFBP-1 From Pretreatment to Week 86
End point description: Growth factor panels for measuring IGFBP-1 were evaluated from screening and at each study visit up to Week 86. Inter-quartile range (Q1-Q3) is 10th to 90th percentile.	
End point type	Secondary
End point timeframe: Pretreatment and Week 86	

End point values	rhIGF-1 QD			
Subject group type	Reporting group			
Number of subjects analysed	29			
Units: percent change				
median (inter-quartile range (Q1-Q3))	-89.6 (-96 to -13)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Changes in Serum Concentration of IGFBP-2 From Pretreatment to Week 86

End point title	Percent Changes in Serum Concentration of IGFBP-2 From Pretreatment to Week 86
End point description: Growth factor panels for measuring IGFBP-2 were evaluated from screening and at each study visit up to Week 86. Subjects who had both pretreatment and Week 86 measurements were included in the analysis. Inter-quartile range (Q1-Q3) is 10th to 90th percentile.	
End point type	Secondary
End point timeframe: Pretreatment and Week 86	

End point values	rhIGF-1 QD			
Subject group type	Reporting group			
Number of subjects analysed	29			
Units: percent change				
median (inter-quartile range (Q1-Q3))	37.9 (-25 to 227)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Changes in Serum Concentration of IGFBP-3 From Pretreatment to Week 86

End point title	Percent Changes in Serum Concentration of IGFBP-3 From Pretreatment to Week 86
End point description: Growth factor panels for measuring IGFBP-3 were evaluated from screening and at each study visit up to Week 86. Subjects who had both pretreatment and Week 86 measurements were included in the analysis. Inter-quartile range (Q1-Q3) is 10th to 90th percentile.	
End point type	Secondary
End point timeframe: Pretreatment and Week 86	

End point values	rhIGF-1 QD			
Subject group type	Reporting group			
Number of subjects analysed	29			
Units: percent change				
median (inter-quartile range (Q1-Q3))	0 (-27 to 48)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Changes in Serum Concentration of ALS From Pretreatment to Week 86

End point title	Percent Changes in Serum Concentration of ALS From Pretreatment to Week 86
End point description: Growth factor panels for measuring ALS were evaluated from screening and at each study visit up to Week 86. Subjects who had both pretreatment and Week 86 measurements were included in the analysis. Inter-quartile range (Q1-Q3) is 10th to 90th percentile.	
End point type	Secondary
End point timeframe: Pretreatment and Week 86	

End point values	rhIGF-1 QD			
Subject group type	Reporting group			
Number of subjects analysed	29			
Units: percent change				
median (inter-quartile range (Q1-Q3))	-7.7 (-36 to 42)			

Statistical analyses

No statistical analyses for this end point

Post-hoc: Increase in Height Velocity From Pretreatment to Week 34: Completer Population

End point title	Increase in Height Velocity From Pretreatment to Week 34: Completer Population
-----------------	--

End point description:

Height was measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. The subject was repositioned between each measurement. The ITT principle was used for missing height velocity. Height velocity during an interval of time is defined as the change in height during the time interval divided by the duration of the time interval. Only subjects in the ITT population who continued past Week 34 were included in the analysis.

End point type	Post-hoc
----------------	----------

End point timeframe:

Pretreatment to Week 34

End point values	rhIGF-1 QD			
Subject group type	Reporting group			
Number of subjects analysed	43			
Units: cm/yr				
arithmetic mean (standard deviation)	1.3 ($\pm$ 3.56)			

Statistical analyses

No statistical analyses for this end point

Post-hoc: Increase in Height Velocity From Pretreatment to Week 86: Completer Population

End point title	Increase in Height Velocity From Pretreatment to Week 86: Completer Population
-----------------	--

End point description:

Height was measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. The subject was repositioned between each measurement. The ITT principle was used for missing height velocity. Height velocity during an interval of time is defined as the change in height during the time interval divided by the duration of the time interval. Only subjects in the ITT population who continued past Week 86 were included in the analysis.

End point type	Post-hoc
----------------	----------

End point timeframe:

Pretreatment to Week 86

End point values	rhIGF-1 QD			
Subject group type	Reporting group			
Number of subjects analysed	30			
Units: cm/yr				
arithmetic mean (standard deviation)	1.3 ($\pm$ 3.58)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Treatment emergent adverse events were collected from Day 1 to Week 86 (approximately 21 months).

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	11.0
--------------------	------

Reporting groups

Reporting group title	rhIGF-1 QD
-----------------------	------------

Reporting group description:

During the treatment phase (Day 1 to Week 86), subjects received SC injections of rhIGF-1 at an initial dose of 60 mcg/kg QD starting on Day 1 (Visit 3). From Week 2 (Visit 4) subsequent dose adjustments were made in order to achieve the target serum IGF-1 concentration for the subject's age and sex.

Serious adverse events	rhIGF-1 QD		
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 45 (4.44%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Congenital, familial and genetic disorders			
Arnold-Chiari Malformation			
subjects affected / exposed	1 / 45 (2.22%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Syringomyelia			
subjects affected / exposed	1 / 45 (2.22%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	1 / 45 (2.22%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Non-serious adverse events	rhIGF-1 QD		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	41 / 45 (91.11%)		
Nervous system disorders			
Headache			
subjects affected / exposed	18 / 45 (40.00%)		
occurrences (all)	32		
General disorders and administration site conditions			
Injection Site Bruising			
subjects affected / exposed	3 / 45 (6.67%)		
occurrences (all)	5		
Pyrexia			
subjects affected / exposed	14 / 45 (31.11%)		
occurrences (all)	18		
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	3 / 45 (6.67%)		
occurrences (all)	3		
Abdominal Pain Upper			
subjects affected / exposed	3 / 45 (6.67%)		
occurrences (all)	4		
Diarrhoea			
subjects affected / exposed	5 / 45 (11.11%)		
occurrences (all)	6		
Stomach Discomfort			
subjects affected / exposed	3 / 45 (6.67%)		
occurrences (all)	3		
Vomiting			
subjects affected / exposed	18 / 45 (40.00%)		
occurrences (all)	21		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	11 / 45 (24.44%)		
occurrences (all)	13		
Nasal Congestion			

subjects affected / exposed	6 / 45 (13.33%)		
occurrences (all)	9		
Pharyngolaryngeal Pain			
subjects affected / exposed	4 / 45 (8.89%)		
occurrences (all)	5		
Rhinorrhoea			
subjects affected / exposed	3 / 45 (6.67%)		
occurrences (all)	3		
Skin and subcutaneous tissue disorders			
Dermatitis Contact			
subjects affected / exposed	3 / 45 (6.67%)		
occurrences (all)	3		
Rash			
subjects affected / exposed	5 / 45 (11.11%)		
occurrences (all)	7		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	6 / 45 (13.33%)		
occurrences (all)	8		
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	6 / 45 (13.33%)		
occurrences (all)	8		
Gastroenteritis Viral			
subjects affected / exposed	3 / 45 (6.67%)		
occurrences (all)	4		
Influenza			
subjects affected / exposed	5 / 45 (11.11%)		
occurrences (all)	6		
Nasopharyngitis			
subjects affected / exposed	3 / 45 (6.67%)		
occurrences (all)	5		
Otitis Media			
subjects affected / exposed	5 / 45 (11.11%)		
occurrences (all)	7		
Sinusitis			

subjects affected / exposed occurrences (all)	4 / 45 (8.89%) 4		
Upper Respiratory Tract Infection subjects affected / exposed occurrences (all)	13 / 45 (28.89%) 24		
Viral Infection subjects affected / exposed occurrences (all)	7 / 45 (15.56%) 13		
Metabolism and nutrition disorders Hypoglycaemia subjects affected / exposed occurrences (all)	5 / 45 (11.11%) 14		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
23 November 2004	The text describing the hypothesis of non-inferiority was rewritten, using standard statistical terms. Text was amended to clarify that GH was a required test at Visit 2 (screening visit) for all subjects, regardless of whether a prior GH stimulation test had been performed. Text was corrected to indicate that both IGF-1 and IGFBP-3 serial sampling were to be performed at Visit 8. The number of subjects required to be screened to achieve the target sample size was revised, based on a lower estimate of the potential drop-out rate. Because GH stimulation tests results are not age-dependent, the restriction that a prior GH stimulation test must have been performed in the past 4 months was removed. Because a 4-month height velocity cannot accurately predict subsequent growth rates, nor is helpful in identifying subjects who can benefit from rhIGF-1 therapy, the 4-month height velocity eligibility criterion was dropped. The phrase, "suspected deletion of the GH gene" was removed from exclusion criterion #1 because it was redundant. The Week 34 visit window was changed to allow for greater flexibility in scheduling. The language regarding statistical case 4 ("non-inferiority test is not significant for either IGF-1 SD score or change in height SD score") was edited for clarity.
20 May 2005	The twice-daily (BID) arm was removed from study design and all subjects received QD dosing with rhIGF-1. To affect an overall mean 24-hour serum IGF-1 SD score closer to intended average of +1, IGF-1 target concentration at sampling times was changed to 1.4 times concentration corresponding to a mean 24-hour SD score of +1. The word "randomized" was deleted from the study title. The study objective regarding BID dosing was deleted. The study objective regarding QD dosing was changed. The number of subjects treated was changed from 90 to 45, reflecting removal of the BID treatment arm. The chronological age eligibility criterion was expanded, and a bone age eligibility criterion was added. A change to the eligibility of subjects with chronic illness was made to allow consideration of enrollment of subjects with chronic illnesses whose condition or medication did not increase risk to subject or the integrity of study. The rhIGF-1 dosing rules were changed from a computation based on the subject's age at randomization to a computation based on a target IGF-1 concentration that more closely approaches the SD score value of +1. The rhIGF-1 dosing instructions were revised to require that rhIGF-1 be taken in the morning, within 30 minutes of breakfast. The starting dose of rhIGF-1 was changed from 40 mcg/kg to 60 mcg/kg to allow the target serum IGF-1 level to be reached more efficiently and to ensure that physiological replacement levels of IGF-1 are maintained for a longer period of time during the study. Explanatory text was added advising that if the morning rhIGF-1 dose has not been taken on Visit days, the Visit must be rescheduled. This was necessary because without rhIGF-1 administration, IGF-1 levels would be low, leading to an unwarranted rhIGF-1 dose increase. The estimated total number of subjects to be screened at Visit 1 was changed from 205 to 100, and the total estimated number of subjects screened at Visit 2 was changed from 135 to 67.
30 January 2006	The treatment period was extended by 12 months (to Week 86). Screening rules were changed to allow prior IGF-1 test results to be averaged with Visit 1 screening results in fulfilment of screening criteria. Screening rules were changed to allow Visit 2 and Visit 3 screening tests to be combined, if all eligibility criteria are were met. An additional safety and efficacy analysis point was added at the end of the extension period (at Week 86). Funduscopic examination was added as a safety endpoint. Urine pregnancy test was added for post-menarchal female subjects. Pregnancy was added as a criterion for removal of a subject from the study. Instructions regarding timing of rhIGF-1 dose administration was changed from "within 30 minutes of a meal or snack" to "shortly before or after (+ 20 minutes) a meal or snack". The text regarding FDA approval of rhIGF-1 (Increlex) for the long-term treatment for growth failure in children with severe primary IGFD was updated.

01 February 2007	The serum IGF-1 SD score adjustment target was raised from +1 to +2. The maximum permitted QD dose of rhIGF-1 was changed from 160 mcg/kg to 240 mcg/kg. The serum IGF-1 concentration target for each subject was modified at each visit to keep targets commensurate with the subjects' chronological age.
------------------	--

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported